000182569 001__ 182569
000182569 005__ 20240229145722.0
000182569 0247_ $$2doi$$a10.3390/cancers14215301
000182569 0247_ $$2pmid$$apmid:36358720
000182569 0247_ $$2altmetric$$aaltmetric:139343118
000182569 037__ $$aDKFZ-2022-02750
000182569 041__ $$aEnglish
000182569 082__ $$a610
000182569 1001_ $$0P:(DE-He78)1fc3c2327d9c213c36fe740ef63e1baa$$aGlatting, Frederik Marcel$$b0$$eFirst author$$udkfz
000182569 245__ $$aSubclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74.
000182569 260__ $$aBasel$$bMDPI$$c2022
000182569 3367_ $$2DRIVER$$aarticle
000182569 3367_ $$2DataCite$$aOutput Types/Journal article
000182569 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1668427027_5814
000182569 3367_ $$2BibTeX$$aARTICLE
000182569 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182569 3367_ $$00$$2EndNote$$aJournal Article
000182569 500__ $$a#EA:E055#
000182569 520__ $$aFAPI-PET is a promising imaging technique for various malignant as well as non-malignant pathologies. In a recent retrospective analysis, we evaluated the diagnostic value of repetitive early FAPI-PET-imaging with FAPI-02, FAPI-46 and FAPI-74 for malignant, inflammatory/reactive and degenerative pathologies. Here, we apply a subgroup analysis to that dataset and describe the tracer-wise uptake kinetic behavior of multiple types of FAPI-positive lesions, which are encountered frequently during clinical routine.A total of 24 cancer patients underwent whole-body FAPI-PET scans, and images were acquired at 10, 22, 34, 46 and 58 min after the administration of 150-250 MBq of 68Ga-FAPI tracer molecules (eight patients each regarding FAPI-02, FAPI-46 and FAPI-74). Standardized uptake values (SUVmax and SUVmean) of healthy tissues, cancer manifestations and non-malignant lesions were measured and target-to-background ratios (TBR) versus blood and fat were calculated for all acquisition timepoints.Differential uptake behavior over time was observed in several subclasses of malignant lesions, inflammatory/reactive lesions and degenerative lesions. These differences over time were particularly manifested in the direct comparison between the uptakes associated with pancreatic carcinoma (stable or increasing over time) and inflammatory lesions of the pancreas (markedly decreasing over time). Furthermore, marked differences were found between the three tracer variants regarding their time-dependent uptake and TBRs within different subclasses of malignant, inflammatory/reactive and degenerative pathologies.Multiple timepoint FAPI-PET/CT is a promising innovative imaging technique that provides additional imaging information compared to single timepoint imaging. Differences in the kinetic behavior of malignant and benign pathologies can facilitate the interpretation of FAPI-positive lesions.
000182569 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000182569 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182569 650_7 $$2Other$$aFAPI
000182569 650_7 $$2Other$$aPET
000182569 650_7 $$2Other$$acancer
000182569 650_7 $$2Other$$adegeneration
000182569 650_7 $$2Other$$afibroblast activation protein
000182569 650_7 $$2Other$$ainflammation
000182569 650_7 $$2Other$$apancreatic carcinoma
000182569 650_7 $$2Other$$apancreatitis
000182569 7001_ $$aHoppner, Jorge$$b1
000182569 7001_ $$aKauczor, Hans-Ulrich$$b2
000182569 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter E$$b3$$udkfz
000182569 7001_ $$aKratochwil, Clemens$$b4
000182569 7001_ $$aGiesel, Frederik L$$b5
000182569 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b6$$udkfz
000182569 7001_ $$aRöhrich, Manuel$$b7
000182569 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers14215301$$gVol. 14, no. 21, p. 5301 -$$n21$$p5301$$tCancers$$v14$$x2072-6694$$y2022
000182569 909CO $$ooai:inrepo02.dkfz.de:182569$$pVDB
000182569 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1fc3c2327d9c213c36fe740ef63e1baa$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000182569 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000182569 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000182569 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000182569 9141_ $$y2022
000182569 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000182569 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000182569 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000182569 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000182569 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000182569 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000182569 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2021$$d2022-11-30
000182569 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000182569 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000182569 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-24T07:56:58Z
000182569 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-24T07:56:58Z
000182569 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-24T07:56:58Z
000182569 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000182569 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000182569 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000182569 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000182569 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000182569 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2021$$d2022-11-30
000182569 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000182569 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x1
000182569 9200_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000182569 980__ $$ajournal
000182569 980__ $$aVDB
000182569 980__ $$aI:(DE-He78)E055-20160331
000182569 980__ $$aI:(DE-He78)E060-20160331
000182569 980__ $$aUNRESTRICTED